Submit a comment
Abstract
Identifying the genetic variants that regulate fasting glucose concentrations may further our understanding of the pathogenesis of diabetes. We therefore investigated the association of fasting glucose levels with SNPs in 2 genome-wide scans including a total of 5,088 nondiabetic individuals from Finland and Sardinia. We found a significant association between the SNP rs563694 and fasting glucose concentrations (P = 3.5 × 10–7). This association was further investigated in an additional 18,436 nondiabetic individuals of mixed European descent from 7 different studies. The combined P value for association in these follow-up samples was 6.9 × 10–26, and combining results from all studies resulted in an overall P value for association of 6.4 × 10–33. Across these studies, fasting glucose concentrations increased 0.01–0.16 mM with each copy of the major allele, accounting for approximately 1% of the total variation in fasting glucose. The rs563694 SNP is located between the genes glucose-6-phosphatase catalytic subunit 2 (G6PC2) and ATP-binding cassette, subfamily B (MDR/TAP), member 11 (ABCB11). Our results in combination with data reported in the literature suggest that G6PC2, a glucose-6-phosphatase almost exclusively expressed in pancreatic islet cells, may underlie variation in fasting glucose, though it is possible that ABCB11, which is expressed primarily in liver, may also contribute to such variation.
Authors
Wei-Min Chen, Michael R. Erdos, Anne U. Jackson, Richa Saxena, Serena Sanna, Kristi D. Silver, Nicholas J. Timpson, Torben Hansen, Marco Orrù, Maria Grazia Piras, Lori L. Bonnycastle, Cristen J. Willer, Valeriya Lyssenko, Haiqing Shen, Johanna Kuusisto, Shah Ebrahim, Natascia Sestu, William L. Duren, Maria Cristina Spada, Heather M. Stringham, Laura J. Scott, Nazario Olla, Amy J. Swift, Samer Najjar, Braxton D. Mitchell, Debbie A. Lawlor, George Davey Smith, Yoav Ben-Shlomo, Gitte Andersen, Knut Borch-Johnsen, Torben Jørgensen, Jouko Saramies, Timo T. Valle, Thomas A. Buchanan, Alan R. Shuldiner, Edward Lakatta, Richard N. Bergman, Manuela Uda, Jaakko Tuomilehto, Oluf Pedersen, Antonio Cao, Leif Groop, Karen L. Mohlke, Markku Laakso, David Schlessinger, Francis S. Collins, David Altshuler, Gonçalo R. Abecasis, Michael Boehnke, Angelo Scuteri, Richard M. Watanabe
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)